MxA启动子-88的基因多态性与干扰素治疗慢性乙型肝炎疗效的关系

Genetic Polymorphisms of the MxA Promoter-88 Site and Response to Interferon Treatment in Hepatitis B Patients

目的探讨抗黏液蛋白A(MxA)启动子-88位点的单核苷酸多态性(SNP)与干扰素(IFN)疗效的关系。方法262例慢性乙型肝炎(CHB)患者给予-αIFN治疗12个月。应用多聚酶链式反应(PCR)及限制片段长度多态性(RFLP)分析宿主的抗病毒蛋白MxA启动子-88位点的SNP,并比较SNP与IFN疗效的关系。结果262例患者中,IFN持久应答(SR)50例(19.1%),非持久应答(NSR)212例(80.9%)。MxA启动子-88位点GT基因型频率在SR组为50.0%,与NSR组的17.5%比较,差异有统计学意义(P<0.01)。结论MxA启动子-88位点为GT杂合基因型的CHB患者对IFN治疗反应好。

Objective To identify the host single nucleotide polymorphisms （SNP） of the MxA promoter 88 site and predict interferon response in hepatitis B patients. Methods 262 chronic hepatitis B patients were treated with α-IFN for 1 year. Single nucleotide polymorphisms of the MxA promoter-88 site were examined by polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） and were compared with the responsiveness of hepatitis B patients to IFN. Results 212 cases were no sustained response （NSR）;50 with sustained response（SR）. The SNP of MxA promoter-88 was found having a significant difference in the genotypic frequency distribution between SR and NSR patients. The rate of GT heterozygote was 50.0% in SR and 17.5% in NSR,P〈0.01. Conclusion Patients with GT genotype at MxA promoter-88 responds well to IFN treatment.